Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

ing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs.  CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014 /PRNewswire-iReach/ -- Maxim ... high-quality peptides that are used solely in scientific experiments, ... two successful years in business, Maxim Peptide, which was ... just launched a new and updated website that now ... blog section has been updated with fascinating articles about ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... Genuity Annual Growth Conference on August 10, 2011 at ... Boston. (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ... accessible in the Investors section of the Company,s website ...
... of bacteria in hospitals is increasing. Bacteria acquire resistance ... incorporating new genes, either from the surrounding environment or ... Portuguese CBA research (University of Lisbon) and the Instituto ... mechanisms of resistance are playing out in the bacterium ...
... tiny hair-like structures that perform feats such as clearing ... location of organs during development, move in mysterious ways. ... similar in appearance to "the wave" created in large ... a pattern of movement around the entire stadium. ...
Cached Biology Technology:Bacterial resistance to antibiotics: The more they resist, the more they divide 2Brandeis lab's artificial cilia spur new thinking in nanotechnology 2
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... in the world to have survived exposure to the vacuum ... Ingemar Jnsson, a researcher at Kristianstad University in Sweden. ... Jnsson had some 3,000 microscopic water bears sent up on ... project, which was supported by the European Space Agency, was ...
... September, in the context of France,s presidency of the ... at the Grand Palais. The GMES (Global Monitoring ... to provide services relating to the environment, climate change, ... on data - mainly Earth observation data - from ...
... clear skies and smooth sailing for oceanic vessels has ... to air pollution and greenhouse gas emissions that impact ... James Winebrake and James Corbett examines "Emission Tradeoffs among ... Oil, Marine Gas Oil, and Marine Diesel Oil," in ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 2
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
... analysis and experiment control software. Records ... on-line and off-line analysis. powerful stimulus ... language allowing the user to customize ... Applications range from basic data logging ...
... • Small design specifically for western ... ,Trays are specifically designed for staining western ... x 25 mm) of the disposable tray ... a significant cost savings to the user. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: